262
Participants
Start Date
May 31, 2006
Primary Completion Date
August 31, 2007
Study Completion Date
August 31, 2007
Placebo
Corresponding placebo is applied for 12weeks
Buprenorphine Transdermal System
Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
Investigational Site, Nagoya
Investigational Site, Okazaki
Investigational Site, Ichikawa
Investigational Site, Matsudo
Investigational Site, Nagareyama
Investigational Site, Fukui-shi
Investigational Site, Annaka
Investigational Site, Takasaki
Investigational Site, Chitose
Investigational Site, Sapporo
Investigational Site, Kako
Investigational Site, Kobe
Investigational Site, Yokohama
Investigational Site, Jōyō
Investigational Site, Sendai
Investigational Site, Isahaya
Investigational Site, Osaka
Investigational Site, Kasukabe
Investigational Site, Koshigaya
Investigational Site, Hikone
Investigational Site, Adachi City
Investigational Site, Arakawa City
Investigational Site, Edogawa City
Investigational Site, Koto
Investigational Site, Setagaya City
Investigational Site, Suginami
Investigational Site, Himi
Investigational Site, Kurobe-shi
Lead Sponsor
Mundipharma K.K.
INDUSTRY